Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H24F3N3O4 |
| Molecular Weight | 451.4389 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=NC(CCOC2=CC=C3C[C@@H](CC(O)=O)C(=O)N(CC(F)(F)F)CC3=C2)=CC=C1
InChI
InChIKey=KSSPHFGIOASRDE-HNNXBMFYSA-N
InChI=1S/C22H24F3N3O4/c1-26-19-4-2-3-17(27-19)7-8-32-18-6-5-14-9-15(11-20(29)30)21(31)28(12-16(14)10-18)13-22(23,24)25/h2-6,10,15H,7-9,11-13H2,1H3,(H,26,27)(H,29,30)/t15-/m0/s1
| Molecular Formula | C22H24F3N3O4 |
| Molecular Weight | 451.4389 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22964516 | https://www.ncbi.nlm.nih.gov/pubmed/11212150Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800013133
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22964516 | https://www.ncbi.nlm.nih.gov/pubmed/11212150
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800013133
SB-273005 is one in a series of orally active nonpeptide vitronectin αvβ3 inhibitors. SB-273005 had been in phase I clinical trials by GlaxoSmithKline for the treatment of postmenopausal osteoporosis and rheumatoid arthritis (RA). However, this research has been discontinued.
Originator
Approval Year
Sample Use Guides
Mice: day 1 (D1) pregnant mice were administered with SB-273005 (3 mg/kg) by gavage at D3, D4 and D5.
Route of Administration:
Oral
Incubation of murine VSMC monocultures with SB-273005 showed a
statistically significant, concentration-dependent decrease
(0.0001–1 uM) in the percentage of viable cells following treatment for up to 12 h. Treatment of VSMC monocultures for 4–24 h with 0.001 uM SB-
273005 produced a statistically significant decrease in viability.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:43 GMT 2025
by
admin
on
Mon Mar 31 18:00:43 GMT 2025
|
| Record UNII |
HG7MY8V9AA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
HG7MY8V9AA
Created by
admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
|
PRIMARY | |||
|
205678-31-5
Created by
admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
|
PRIMARY | |||
|
9868426
Created by
admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Osteoporosis. No toxicity in humans;
dose-dependent heart valve lesions in mice
(species-specific
|
